Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

As part of a multi-product collaboration, Asimov’s CHO Edge system enabled a high performance cell line for a first-in-class bispecific antibody, achieving clonal titers of over 10 g/L in a platform fed-batch process 

‍

BOSTON, MA, September 14, 2026–Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer. As part of a broader collaboration across multiple products, Asimov successfully delivered a cell line for Sidewinder’s bispecific antibody candidate for solid tumors.

‍

“We are excited to be partnering with Sidewinder Therapeutics to advance their novel bispecific, which represents a powerful approach to targeting and treating solid tumors,” said Alec Nielsen, co-founder and CEO at Asimov. “Complex molecules such as Sidewinder’s 4-chain bispecific can be challenging to express, and achieving such high titers for this molecule is a testament to the strength of both our team and our CHO Edge System.”

‍

Asimov has worked closely with the Sidewinder team on a custom cell line development program for this 4-chain bispecific antibody. In order to achieve the required expression levels and quality attributes, Sidewinder relied on Asimov’s CHO Edge system, which combines a GS knock-out CHO host, hyperactive transposase, genetic parts library, and Kernel, Asimov's AI-driven genetic design software.

‍

“With a pipeline of first-in-class bispecific ADCs, we needed to find a cell line development partner with the technical capabilities required to deliver high expression levels while simultaneously achieving consistent product quality,” said Eric Murphy, Ph.D., co-founder and CEO at Sidewinder. “The team at Asimov has exceeded expectations, and we’re excited to be progressing toward the clinic with such a high performing cell line.”

‍

About Asimov

Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations.  

‍

Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com.  

‍

About Sidewinder Therapeutics

Sidewinder Therapeutics is developing next-generation bispecific ADCs designed to expand the therapeutic window through enhanced tumor specificity and internalization. Founded in 2023, Sidewinder is headquartered in San Diego and has raised a total of $162 million from a world-class investor syndicate. For more information, visit www.sidewinderbio.com.

‍